Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.

Acorda buys Civitas and its Parkinson’s candidate for $525 million, ending the latter’s intent to go public. Pharmacyclics and Servier unwind their 2009 agreement to co-develop oncology drug abexinostat.

Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.